Porous silicon based intravitreal platform for dual-drug loading and controlled release towards synergistic therapy

References

• Aiello LP, Avery RL, Arrigg PG, et al. (1994). Vascular endothelial growth-factor in ocular fluid of patients with diabetic-retinopathy and other retinal disorders. N Engl J Med 331:1480–7.
   PubMed Web of Science ®Google Scholar
• Anglin EJ, Cheng LY, Freeman WR, Sailor MJ. (2008). Porous silicon in drug delivery devices and materials. Adv Drug Deliv Rev 60:1266–77.
   PubMed Web of Science ®Google Scholar
• Antonetti DA, Klein R, Gardner TW. (2012). Diabetic retinopathy. N Engl J Med 366:1227–39.
   PubMed Web of Science ®Google Scholar
• Aroney C, Fraser-Bell S, Lamoureux EL, et al. (2016). Vision-related quality of life outcomes in the BEVORDEX study: a clinical trial comparing ozurdex sustained release dexamethasone intravitreal implant and bevacizumab treatment for diabetic macular edema. Invest Ophthalmol Vis Sci 57:5541–6.
   PubMed Web of Science ®Google Scholar
• Banerjee PJ, Quartilho A, Bunce C, et al. (2017). Slow-release dexamethasone in proliferative vitreoretinopathy. Ophthalmology 124:757–67.
   PubMed Web of Science ®Google Scholar
• Batman C, Ozdamar Y. (2010). The relation between bevacizumab injection and the formation of subretinal fibrosis in diabetic patients with panretinal photocoagulation. Ophthalmic Surg Lasers Imaging 41:190–5.
   PubMedGoogle Scholar
• Blumenkranz MS, Claflin A, Hajek AS. (1984). Selection of therapeutic agents for intraocular proliferative disease - cell-culture evaluation. Arch Ophthalmol 102:598–604.
   PubMed Web of Science ®Google Scholar
• Calvo P, Ferreras A, Al Adel F, et al. (2015). Dexamethasone intravitreal implant as adjunct therapy for patients with wet age-related macular degeneration with incomplete response to ranibizumab. Br J Ophthalmol 99:723.
   PubMed Web of Science ®Google Scholar
• Castro E, Mosquera V, Katime I. (2012). Dual drug release of triamterene and aminophylline from poly (N-isopropylacrylamide) hydrogels regular paper. Nanomater Nanotechnol 2:6.
   Web of Science ®Google Scholar
• Cheng L, Anglin E, Cunin F, et al. (2008). Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drugdelivery vehicle. Br J Ophthalmol 92:705–11.
   PubMed Web of Science ®Google Scholar
• Chhablani J, Nieto A, Hou HY, et al. (2013). Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system. Invest Ophthalmol Vis Sci 54:1268–79.
   PubMed Web of Science ®Google Scholar
• Daniel E, Toth CA, Grunwald JE, et al. (2014). Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology 121:656–66.
   PubMed Web of Science ®Google Scholar
• Feng L, Gai S, He F, et al. (2017). Multifunctional mesoporous ZrO2 encapsulated upconversion nanoparticles for mild NIR light activated synergistic cancer therapy. Biomaterials 147:39–52.
   PubMed Web of Science ®Google Scholar
• Funatsu H, Yamashita H, Noma H, et al. (2002). Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 133:70–7.
   PubMed Web of Science ®Google Scholar
• Garweg JG, Wegmann-Burns M, Goldblum D. (2006). Effects of daunorubicin, mitomycin C, azathioprine and cyclosporin A on human retinal pigmented epithelial, corneal endothelial and conjunctival cell lines. Graefes Arch Clin Exp Ophthalmol 244:382–9.
   PubMed Web of Science ®Google Scholar
• Gewirtz DA. (1999). A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. Biochem Pharmacol 57:727–41.
   PubMed Web of Science ®Google Scholar
• Grossniklaus HE, Ling JX, Wallace TM, et al. (2002). Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis 8:119–26.
   PubMed Web of Science ®Google Scholar
• Hartmann KI, Nieto A, Wu EC, et al. (2013). Hydrosilylated porous silicon particles function as an intravitreal drug delivery system for daunorubicin. J Ocul Pharmacol Ther 29:493–500.
   PubMed Web of Science ®Google Scholar
• Hede K. (2009). Low-dose anthracyclines may block HIF-1 and stop tumor growth. J Natl Cancer Inst 101:368–70.
   PubMedGoogle Scholar
• Hou H, Wang C, Nan K, et al. (2016). Controlled release of dexamethasone from an intravitreal delivery system using porous silicon dioxide. Invest Ophthalmol Vis Sci 57:557–66.
   PubMed Web of Science ®Google Scholar
• Hou HY, Huffman K, Rios S, et al. (2015). A novel approach of daunorubicin application on formation of proliferative retinopathy using a porous silicon controlled delivery system: pharmacodynamics. Invest Ophthalmol Vis Sci 56:2755–63.
   PubMed Web of Science ®Google Scholar
• Hou HY, Nieto A, Ma FY, et al. (2014). Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon. J Control Release 178:46–54.
   PubMed Web of Science ®Google Scholar
• Hu CMJ, Zhang LF. (2012). Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol 83:1104–11.
   PubMed Web of Science ®Google Scholar
• Hueber A, Weller M, Welsandt G, et al. (2003). Characterization of daunorubicin-induced apoptosis in retinal pigment epithelial cells: modulation by CD95L. Invest Ophthalmol Vis Sci 44:2851–7.
   PubMed Web of Science ®Google Scholar
• Hui YN, Hu D. (1999). Prevention of experimental proliferative vitreoretinopathy with daunomycin and triamcinolone based on the time course of the disease. Graefes Arch Clin Exp Ophthalmol 237:601–5.
   PubMed Web of Science ®Google Scholar
• Hwang JC, Del Priore LV, Freund KB, et al. (2011). Development of subretinal fibrosis after anti-VEGF treatment in neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 42:6–11.
   PubMedGoogle Scholar
• Jaffuel D, Roumestan C, Balaguer P, et al. (2001). Correlation between different gene expression assays designed to measure trans-activation potencies of systemic glucocorticoids. Steroids 66:597–604.
   PubMed Web of Science ®Google Scholar
• Krebs I, Glittenberg C, Ansari-Shahrezaei S, et al. (2013). Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration. Br J Ophthalmol 97:1443–6.
   PubMed Web of Science ®Google Scholar
• Kuiper EJ, Van Nieuwenhoven FA, De Smet MD, et al. (2008). The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS One 3:e2675.
   PubMed Web of Science ®Google Scholar
• Kumeria T, Mcinnes SJP, Maher S, Santos A. (2017). Porous silicon for drug delivery applications and theranostics: recent advances, critical review and perspectives. Expert Opin Drug Deliv 14:1407–22.
   PubMed Web of Science ®Google Scholar
• Kwak HW, D'amico DJ. (1992). Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol 110:259–66.
   PubMed Web of Science ®Google Scholar
• Maturi RK, Pollack A, Uy HS, et al. (2016). Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year mead study. Retina 36:1143–52.
   PubMed Web of Science ®Google Scholar
• Nieto A, Hou HY, Sailor MJ, et al. (2013). Ocular silicon distribution and clearance following intravitreal injection of porous silicon microparticles. Exp Eye Res 116:161–8.
   PubMed Web of Science ®Google Scholar
• Rofagha S, Bhisitkul RB, Boyer DS, et al. (2013). Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 120:2292–9.
   PubMed Web of Science ®Google Scholar
• Santana M, Wiedemann P, Kirmani M, et al. (1984). Daunomycin in the treatment of experimental proliferative vitreoretinopathy: retinal toxicity of intravitreal daunomycin in the rabbit. Graefes Arch Clin Exp Ophthalmol 221:210–3.
   PubMed Web of Science ®Google Scholar
• Schneider CA, Rasband WS, Eliceiri KW. (2012). NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9:671–5.
   PubMed Web of Science ®Google Scholar
• Schwartz SG, Scott IU, Stewart MW, Flynn HW Jr. (2016). Update on corticosteroids for diabetic macular edema. Clin Ophthalmol 10:1723–30.
   PubMed Web of Science ®Google Scholar
• Semkova I, Muether PS, Kuebbeler M, et al. (2011). Recruitment of blood-derived inflammatory cells mediated via tumor necrosis factor-alpha receptor 1b exacerbates choroidal neovascularization. Invest Ophthalmol Vis Sci 52:6101–8.
   PubMed Web of Science ®Google Scholar
• Song BT, Wu CT, Chang J. (2012). Dual drug release from electrospun poly(lactic-co-glycolic acid)/mesoporous silica nanoparticles composite mats with distinct release profiles. Acta Biomater 8:1901–7.
   PubMed Web of Science ®Google Scholar
• Su CW, Chiang CS, Li WM, et al. (2014). Multifunctional nanocarriers for simultaneous encapsulation of hydrophobic and hydrophilic drugs in cancer treatment. Nanomedicine 9:1499–515.
   PubMed Web of Science ®Google Scholar
• Tekade RK, Dutta T, Gajbhiye V, Jain NK. (2009). Exploring dendrimer towards dual drug delivery: pH responsive simultaneous drug-release kinetics. J Microencapsul 26:287–96.
   PubMed Web of Science ®Google Scholar
• Telander DG. (2011). Inflammation and age-related macular degeneration (AMD). Semin Ophthalmol 26:192–7.
   PubMed Web of Science ®Google Scholar
• Van Geest RJ, Lesnik-Oberstein SY, Tan HS, et al. (2012). A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. Br J Ophthalmol 96:587–90.
   PubMed Web of Science ®Google Scholar
• Wang CF, Makila EM, Kaasalainen MH, et al. (2015). Dual-drug delivery by porous silicon nanoparticles for improved cellular uptake, sustained release, and combination therapy. Acta Biomater 16:206–14.
   PubMed Web of Science ®Google Scholar
• Wang CY, Hou HY, Nan KH, et al. (2014). Intravitreal controlled release of dexamethasone from engineered microparticles of porous silicon dioxide. Exp Eye Res 129:74–82.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang VM, Chan CC. (2011). The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment. Eye (Lond) 25:127–39.
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, Diabetic Retinopathy Clinical Research, N, et al. (2016). Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a comparative effectiveness randomized clinical trial. Ophthalmology 123:1351–9.
   Google Scholar
• Wiedemann P, Hilgers RD, Bauer P, Heimann K. (1998). Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group. Am J Ophthalmol 126:550–9.
   PubMed Web of Science ®Google Scholar
• Wiedemann P, Kirmani M, Santana M, et al. (1983). Control of experimental massive periretinal proliferation by daunomycin: dose-response relation. Graefes Arch Clin Exp Ophthalmol 220:233–5.
   PubMed Web of Science ®Google Scholar
• Xu JT, He F, Cheng ZY, et al. (2017a). Yolk-structured upconversion nanoparticles with biodegradable silica shell for FRET sensing of drug release and imaging-guided chemotherapy. Chem Mater 29:7615–28.
   Web of Science ®Google Scholar
• Xu JT, Yang PP, Sun MD, et al. (2017b). Highly emissive dye-sensitized upconversion nanostructure for dual-photosensitizer photodynamic therapy and bioimaging. ACS Nano 11:4133–44.
   PubMed Web of Science ®Google Scholar
• Yamazaki Y, Hasebe Y, Egawa K, et al. (2006). Anthracyclines, small-molecule inhibitors of hypoxia-inducible factor-1 alpha activation. Biol Pharm Bull 29:1999–2003.
   PubMed Web of Science ®Google Scholar
• Young M, Chui L, Fallah N, et al. (2014). Exacerbation of choroidal and retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. Retina 34:1308–15.
   PubMed Web of Science ®Google Scholar